Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025

Close Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity Strasbourg, France – Montreal, Canada – Boston, United States, April 1, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces that it will be presenting new preclinical and clinical data on its key oncology programs – DT-7012, and DT-9081, alongside preclinical findings on its PAR2 biased negative allosteric modulator ( NAM ) program – at the upcoming American Association for Cancer Research ( AACR ) Annual Meeting 2025 , taking place in Chicago, US from 25-30 April 2025. The poster presentations will highlight Domain’s progress in leveraging GPCR-targeting therapies to modulate the tumor microenvironment and enhance anti-cancer immune responses. Details of the poster presentations are as follows: Poster Title: Comprehensive Characterization of DT-7012, a Differentiated CCR8-Depleting Antibody for the Treatment of Solid Tumors Session Category: Experimental and Molecular Therapeutics Session Title: Antireceptors and Other Biological Therapeutic Agents Date and Time: Sunday 27 th April 2025, 14:00 – 17:00 CDT Location: Poster Section 15 Poster Board Number: 4 Abstract Number: 7080 DT-7012 – A Differentiated CCR8-Depleting Antibody for Solid Tumors DT-7012 is a highly selective, fully humanized monoclonal antibody targeting CCR8, a receptor predominantly expressed on tumor-resident regulatory T cells ( Tregs ), which suppress anti-tumor immunity. The study characterizes DT-7012’s binding properties, effector functions, and Treg-depleting activity, supporting its transition into clinical development. Poster Title: Clinical PK, PD and safety analysis of a phase I clinical trial of DT-9081, an EP4R-antagonist, for RP2D determination in patients with advanced solid tumors Session Category: Clinical Research Session Title: Modifiers of the Tumor Microenvironment Date and Time: Monday 28 th April 2025, 14:00 – 17:00 CDT Location: Poster Section 30 Poster Board Number: 8 Abstract Number: 7450 DT-9081 – Phase I Clinical Data of an EP4R Antagonist for Advanced Solid Tumors DT-9081 is an oral EP4 receptor ( EP4R ) antagonist designed to inhibit growth by blocking prostaglandin E2 ( PGE2 )-mediated immune suppression. Interim Phase I results demonstrate DT-9081’s favorable safety profile, linear pharmacokinetics, and dose-dependent inhibition of EP4R signaling, with data supporting the recommended Phase II dose ( RP2D ). Poster Title: PAR2 inhibitors reduce resistance to immunotherapy against cancer Session Category: Immunology Session Title: Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 2 Date and Time: Tuesday 29 th April, 14:00 – 17:00 CDT Location: Poster Section 40 Poster Board Number: 9 Abstract Number: 6606 PAR2 – Pivotal driver of resistance to immune checkpoint blockade ( ICB ) and T cell dysfunction in cancer PAR2 biased NAM represents a transformative breakthrough in immuno-oncology, targeting tumor resistance to ICB. Preclinical findings demonstrate the unique mode of action of PAR2 inhibition. By reshaping the tumor microenvironment, it reduces immunosuppressive macrophages and increases antigen presentation, fostering robust anti-tumor immune responses and thereby improving patient outcomes. Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “These promising preclinical and clinical results for DT-7012 and DT-9081, alongside the preclinical findings on our PAR2 biased NAM demonstrate Domain’s unmatched knowledge in leveraging deep receptor biology to develop differentiated oncology treatments. We look forward to sharing these promising insights with the scientific community as we continue to push the boundaries to ultimately deliver better treatments and transform patients’ lives.” Abstracts are available in an online itinerary planner found here and will be available in an online only supplement to the AACR journal Cancer Research one month after the conference. ENDS For more information, please contact: Optimum Strategic Communications Mary Clark, Zoe Bolt, Elena Bates +44 (0) 203 882 9621 [email protected] Download the pdf

The release as fetched from its publisher. domaintherapeutics.com ↗